August 2019 Updates on ED Clinical Trials

There is a lot going on in our Emergency Department! Thank you for your continued support to make these trials successful. Keep moving that needle of science forward as we provide high-quality healthcare. --Bory Kea

ED Study:

- **Heart Failure Pro BNP Study:** Evaluating a new pro-BNP assay in patients with heart failure (for diagnosis and severity assessment)
  PI: Kea; Coordinator: Joy Kim
  Inclusion criteria: >21 yo, with SOB and/or edema; enrollment within 11hrs of presentation
  Exclusion: Trauma, on dialysis, prisoner, homelessness, and prior enrollment
  Enrollment-to-date: **26**
  Site Goal: 100 (enrollment period through end of 2019)

- **HydraSense**: A novel device for distal perfusion: currently enrolling in kids and adults
  PI: Sheridan; Coordinator: Nancy Le
  Enrollment-to-date: **33**
  Goal: 600 until October
  This study requires NO work or input from RNs or MDs. The study team will work around staff with any patients they enroll to make sure and prioritize your time with them over the study.
  This study will transition in October to a pediatric dehydration device study if able to enroll site goal

- **Solace**: Wearable technology for physiologic monitoring of adolescent suicidality: enrolls adolescents presenting with suicidality with goal of developing objective/physiologic markers that correlate with escalating suicidality
  PI: Sheridan; Coordinator: Nancy Le
  Enrollment-to-date: **67**
  Goal: 200 across the pediatric ER and inpatient adolescent psychiatric unit at Unity

- **BOOST-3 Brain Oxygen Optimization in Severe TBI Phase-3 Trial:**
  PI: Daya, Coordinator: Jenny Cook
  Registered with ClinicalTrials.gov: NCT03754114
  Status: Pre-study preparations
  Info: BOOST 3 is a trial being run through the nationwide SIREN Network.OHSU is a “award hub”, and 4 of our OHSU network sites will also be participating in this trial (OSU, Duke, University of Utah, and University of Rochester Medical Center). A total of 45 sites will be enrolling patients throughout the duration of this trial.

BOOST 3 will operate under EFIC (Exception from Informed Consent) rules, and is currently conducting community consultation activities in the Portland Metro Area. Enrollment is expected to begin in **October 2019** at OHSU.

ICU-ED Sepsis Studies:

- **VICTAS:** Giving *vitamin C, thiamine, and steroids* in patients with **septic shock** or **respiratory failure from sepsis** (ventilator, BiPAP, HFNC dependent)
  Site Enrollment: **23**
  Site Goal: 140 until September 2021 (1 per week)
  Status: Closed to enrollment
  Total Enrollment Goal: 500 until September 2021

- **CLOVERS**: Using *liberal fluid strategy vs early vasopressor strategy* in patients with **Septic Shock** (sepsis + hypotension)
  Site Enrollment: **71**
  Site Goal: 146 April 2021 (1 per week)
  Total Enrollment Goal: 2200 until April 2021

If you have any issues with any of the studies or feedback for improvement, please let me know so that we can improve these studies for everyone.

Research Coordinators may approach you for these studies and request that you introduce them to the patient or family and answer if enrollment is appropriate. (All coordinators are trying to get into medical school so please be nice to them. - Akram).
Questions for ICU team:

Contact our study team Smartweb à Last Name à PRISM **(#11912)**
Our team is available 8 AM-9PM to answer your questions.
Site PI Akram Khan (khana@ohsu.edu) pager à 15351 or text/cell 503-449-4314 (24 hours).